Impact of Timing of Pacemaker Reimplantation Following Transvenous Lead Removal of Infected Cardiac Implantable Electronic Devices on Hospital Outcomes
Abstract Body (Do not enter title and authors here): Background The optimal timing of pacemaker reimplantation following transvenous lead removal (TLR) of infected cardiac implantable electronic device (CIED) remains unclear. Objective Our study aimed to assess the impact of timing to pacemaker reimplantation after TLR of infected CIED on hospital outcomes. Method Using the Nationwide Readmissions Database, patients aged ≥18 years who underwent new pacemaker implantation with percutaneous approach following TLR of infected CIED from 2017 to 2020 were identified. The study population was stratified based on the timing of pacemaker reimplantation following TLR of infected CIED: early (<5 days) vs delayed (≥5 days). Weighted-propensity-score matched conditional multivariable logistic regressions were performed to determine the impact of the timing on various outcomes. Results In our study, 469 (66.9%) patients received early device reimplantation, and 232 (33.1%) patients received delayed device reimplantation (≥5 days). Post-procedurally, patients in the delayed group had a higher risk of prolonged hospital stay (95% CI OR: 42.37 (6.36 – 282.11); p<0.01) and non-home discharge (95% CI OR: 2.00 (1.35 – 2.95), p<0.01). There was no significant difference between both groups in the early mortality, 30-day readmission, and procedural complications. Conclusion Our study suggests that time-to-device reimplantation from TLR of infected CIED did not affect the overall short-term in-hospital outcomes. However, delayed device reimplantation was associated with a higher rate of prolonged hospital stay and non-home discharge.
Ang, Qi Xuan
( Michigan State University/Sparrow Hospital
, Lansing
, Michigan
, United States
)
Tan, Min Choon
( Saint Michael's Medical Center
, Newark
, New Jersey
, United States
)
Yeo, Yong Hao
( William Beaumont Hospital Royal Oak
, ROYAL OAK
, Michigan
, United States
)
Rattanawong, Pattara
( Massachusetts General Hospital
, Boston
, Massachusetts
, United States
)
Sorajja, Dan
( MAYO CLINIC
, Phoenix
, Arizona
, United States
)
Scott, Luis
( MAYO CLINIC
, Scottsdale
, Arizona
, United States
)
Cha, Yong-mei
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Russo, Andrea
( Cooper University Hospital
, Moorestown
, New Jersey
, United States
)
Lee, Justin
( Cleveland Clinic
, Cleveland
, Ohio
, United States
)
Author Disclosures:
Qi Xuan Ang:DO have relevant financial relationships
;
Employee:University of Michigan Health Sparrow Hospital:Active (exists now)
| Min Choon Tan:DO NOT have relevant financial relationships
| Yong Hao Yeo:DO NOT have relevant financial relationships
| Pattara Rattanawong:No Answer
| Dan Sorajja:DO NOT have relevant financial relationships
| Luis Scott:DO NOT have relevant financial relationships
| Yong-mei Cha:No Answer
| Andrea Russo:DO have relevant financial relationships
;
Researcher:Bayer:Past (completed)
; Speaker:Boston Scientific:Past (completed)
; Speaker:Medtronic:Active (exists now)
; Speaker:Abbott:Past (completed)
; Consultant:Pacemate:Active (exists now)
; Consultant:Medtronic:Active (exists now)
; Consultant:Boston Scientific:Active (exists now)
; Consultant:Biotronik:Active (exists now)
; Consultant:Biosense Webster:Active (exists now)
; Consultant:Bayer:Past (completed)
; Consultant:Atricure:Active (exists now)
; Consultant:Abbott:Active (exists now)
; Researcher:Abbott:Active (exists now)
; Researcher:Medtronic:Past (completed)
; Researcher:Boston Scientific:Active (exists now)
| Justin Lee:DO have relevant financial relationships
;
Speaker:Boston Scientific:Past (completed)